CHRM1 and neoplasm: In pancreatic ductal adenocarcinoma (PDAC), prominent differential actions of muscarinic receptor subtypes are reported, i.e., M1R activation protects against neoplasia whereas M3R activation promotes pancreatic cancer progression.